About: Faricimab

Property	Value
dbo:abstract	Faricimab ist ein Arzneistoff zur Behandlung bestimmter Erkrankungen der Netzhaut des Auges. Unter dem Handelsnamen Vabysmo (Hersteller: Genentech) wurde Faricimab von der amerikanischen Behörde FDA im Januar 2022 in den USA zugelassen für die Therapie der neovaskulären (feuchten) altersbedingten Makuladegeneration (neovascular (wet) age-related macular degeneration, nAMD) und des diabetischen Makulaödems (diabetic macular edema, DME). Faricimab ist ein monoklonaler Antikörper, der bispezisch wirkt. Das Medikament wird in den Glaskörper des Auges (intravitreal) injiziert. (de) Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody, to target both vascular endothelial growth factor (VEGF), and angiopoietin 2 (Ang-2) inhibitor. By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection (injection into the eye) by an ophthalmologist. Faricimab was developed by Roche. Faricimab was approved for medical use in the United States in January 2022, and in the European Union in September 2022. (en) Фарицимаб — лекарственный препарат, моноклональноe антитело для лечения возрастной макулярной дегенерации. Одобрен для применения: США (2022) (ru)
dbo:alternativeName	Vabysmo (en)
dbo:casNumber	1607793-29-2
dbo:drugbank	DB15303
dbo:fdaUniiCode	QC4F7FKK7I
dbo:kegg	D11516
dbo:thumbnail	wiki-commons:Special:FilePath/Antibodyigg.png?width=300
dbo:wikiPageExternalLink	https://druginfo.nlm.nih.gov/drugportal/name/faricimab
dbo:wikiPageID	58563686 (xsd:integer)
dbo:wikiPageLength	17779 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1118774209 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Pregnancy dbr:Endothelium dbr:Hoffmann-La_Roche dbr:Retina dbr:Uveitis dbr:Visual_acuity dbr:Intravitreal_injection dbr:Age-related_macular_degeneration dbr:Preclinical_development dbr:Vascular_endothelial_growth_factor dbr:Endothelial_cells dbr:Branch_retinal_vein_occlusion dbr:Monoclonal_antibody dbr:Conjunctiva dbr:Committee_for_Medicinal_Products_for_Human_Use dbr:Macular_degeneration dbc:Ophthalmology_drugs dbc:Genentech_brands dbr:Aflibercept dbr:Drug_development dbr:European_Medicines_Agency dbr:Angiopoietin dbr:Central_retinal_vein_occlusion dbr:Diabetic_macular_edema dbc:Angiogenesis_inhibitors dbr:International_Nonproprietary_Name dbr:Hypersensitivity dbr:Vascular_endothelial_growth_factor_A dbc:Monoclonal_antibodies dbc:Hoffmann-La_Roche_brands dbr:Bispecific_monoclonal_antibody dbr:Infection dbr:Ophthalmologist dbr:Ranibizumab dbr:Phases_of_clinical_research dbr:Age_related_macular_degeneration dbr:Phase_III_clinical_research dbr:Indicated dbr:Angiopoietin_2 dbr:VEGF-A
dbp:atcPrefix	None (en)
dbp:c	6506 (xsd:integer)
dbp:casNumber	1607793 (xsd:integer)
dbp:dailymedid	Faricimab (en)
dbp:drugbank	DB15303 (en)
dbp:h	9968 (xsd:integer)
dbp:kegg	D11516 (en)
dbp:legalAu	S4 (en)
dbp:legalCa	Rx-only (en)
dbp:legalCaComment	/Schedule D (en)
dbp:legalEu	Rx-only (en)
dbp:legalUs	Rx-only (en)
dbp:mabType	mab (en)
dbp:n	1724 (xsd:integer)
dbp:o	1026 (xsd:integer)
dbp:routesOfAdministration	dbr:Intravitreal_injection
dbp:s	45 (xsd:integer)
dbp:source	zu (en)
dbp:synonyms	RO6867461; RG7716; faricimab-svoa (en)
dbp:target	dbr:Angiopoietin_2 dbr:VEGF-A
dbp:tradename	Vabysmo (en)
dbp:type	mab (en)
dbp:unii	QC4F7FKK7I (en)
dbp:wikiPageUsesTemplate	dbt:Monoclonals_for_bone,_musculoskeletal,_circulatory,_and_neurologic_systems dbt:Cite_web dbt:Infobox_drug dbt:Nbsp dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Use_American_English dbt:Use_dmy_dates dbt:Growth_factor_receptor_modulators dbt:ClinicalTrialsGov dbt:Ocular_vascular_disorder_agents
dcterms:subject	dbc:Ophthalmology_drugs dbc:Genentech_brands dbc:Angiogenesis_inhibitors dbc:Monoclonal_antibodies dbc:Hoffmann-La_Roche_brands
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug
rdfs:comment	Faricimab ist ein Arzneistoff zur Behandlung bestimmter Erkrankungen der Netzhaut des Auges. Unter dem Handelsnamen Vabysmo (Hersteller: Genentech) wurde Faricimab von der amerikanischen Behörde FDA im Januar 2022 in den USA zugelassen für die Therapie der neovaskulären (feuchten) altersbedingten Makuladegeneration (neovascular (wet) age-related macular degeneration, nAMD) und des diabetischen Makulaödems (diabetic macular edema, DME). Faricimab ist ein monoklonaler Antikörper, der bispezisch wirkt. Das Medikament wird in den Glaskörper des Auges (intravitreal) injiziert. (de) Фарицимаб — лекарственный препарат, моноклональноe антитело для лечения возрастной макулярной дегенерации. Одобрен для применения: США (2022) (ru) Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody, to target both vascular endothelial growth factor (VEGF), and angiopoietin 2 (Ang-2) inhibitor. By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection (injection into the eye) by an ophthalmologist. (en)
rdfs:label	Faricimab (en) Faricimab (de) Фарицимаб (ru)
owl:sameAs	wikidata:Faricimab dbpedia-de:Faricimab dbpedia-ru:Faricimab https://global.dbpedia.org/id/9KcoY
prov:wasDerivedFrom	wikipedia-en:Faricimab?oldid=1118774209&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Antibodyigg.png
foaf:isPrimaryTopicOf	wikipedia-en:Faricimab
is dbo:wikiPageRedirects of	dbr:Vabysmo dbr:Faricimab-svoa
is dbo:wikiPageWikiLink of	dbr:Macular_degeneration dbr:Vabysmo dbr:List_of_therapeutic_monoclonal_antibodies dbr:Faricimab-svoa
is foaf:primaryTopic of	wikipedia-en:Faricimab